Company: PFSA
Filing Date: 2025-04-28
Form Type: S-4/A
Source: 0001213900-25-035718
Chunk: 204

Company: Profusa, Inc.
Filing Date: 2025-04-28
Form: S-4/A
Chunk 204
---
 fluctuations in the price of New Profusa’s securities could contribute to the loss of all or part of your investment. Prior to the Business Combination, there has not been a public market for Profusa’s securities. Accordingly, the valuation ascribed to Profusa may not be indicative of the price that will prevail in the trading market following the Business Combination. If an active market for New Profusa’s securities develops and continues, the trading price of New Profusa’s securities following the Business Combination could be volatile and subject to wide fluctuations in response to various factors, some of which are beyond New Profusa’s control. Any of the factors listed below could have a negative impact on your investment in New Profusa’s securities and New Profusa’s securities may trade at prices significantly below the price you paid for them. In such circumstances, the trading price of New Profusa’s securities may not recover and may experience a further decline. Factors affecting the trading price of New Profusa’s securities may include: •changes in financial estimates by New Profusa or by any securities analysts who might cover its stock; •proposed changes to laws in the U.S. or foreign jurisdictions relating to New Profusa’s business, or speculation regarding such changes; •conditions or trends in the diagnostic, medical device or biotechnology industries; •stock market price and volume fluctuations of comparable companies; •announcements by New Profusa or its competitors of significant acquisitions, strategic partnerships or divestitures; •significant lawsuits or announcements of investigations or regulatory scrutiny of its operations or lawsuits filed against New Profusa; •recruitment or departure of key personnel; •investors’ general perception of New Profusa’s business or management; •trading volume of New Profusa Common Stock; •overall performance of the equity markets; •publication of research reports about New Profusa or its industry or positive or negative recommendations or withdrawal of research coverage by securities analysts; •the impacts of the ongoing COVID -19pandemic and related restrictions; •general political and economic conditions; and •other events or factors, many of which are beyond Profusa’s control. In addition, in the past, stockholders have initiated class action lawsuits against public companies following periods of volatility in the market prices of these companies’ stock. Such litigation, if instituted against New Profusa, could cause it to incur substantial costs and divert management’s attention and resources from its business. 93 Upon the completion of the Business Combination, the Profusa shareholders will be able to control or exert substantial influence over all matters submitted to our stock